Podcasts about biometry

In this episdoe, we explore how biometry is used to measure key metrics like Biparietal Diameter (BPD) and Head Circumference (HC), shedding light on what these measurements reveal about your baby's growth and development. We talk about their role in predicting potential challenges during labor, and how they help ensure a safe and healthy birth. From understanding head size's impact on delivery to offering expectant parents valuable insights, this episode unpacks the critical connection between fetal head measurements and the labor process.   YouTube: Dive deeper into pregnancy tips and stories atyoutube.com/maternalresources . Instagram: Follow us for daily inspiration and updates at @maternalresources . Facebook: Join our community at facebook.com/IntegrativeOB Tiktok: NatureBack Doc on TikTok Grab Our Book! Check out The NatureBack Method for Birth—your guide to a empowered pregnancy and delivery. Shop now at naturebackbook.myshopify.com .

In this episode, we explore GreenMan, an innovative virtual tool revolutionizing patient consultations. Designed to leverage a patient's unique biometry, GreenMan offers a tangible visualization of post-surgery vision outcomes, empowering informed decision-making and improving satisfaction. Our experts discuss the clinical challenges that inspired this solution, detailing how they integrated GreenMan into their practice workflow. Learn how this advanced technology enhances patient education, streamlines lens selection, and delivers better visual outcomes. Want to see GreenMan in action? Click here to view the demo. Tune in to discover how GreenMan is setting a new standard in personalized eye care.

In this episode, we explore GreenMan, an innovative virtual tool revolutionizing patient consultations. Designed to leverage a patient's unique biometry, GreenMan offers a tangible visualization of post-surgery vision outcomes, empowering informed decision-making and improving satisfaction. Our experts discuss the clinical challenges that inspired this solution, detailing how they integrated GreenMan into their practice workflow. Learn how this advanced technology enhances patient education, streamlines lens selection, and delivers better visual outcomes. Want to see GreenMan in action? Click here to view the demo. Tune in to discover how GreenMan is setting a new standard in personalized eyecare.

In this episode, we explore GreenMan, an innovative virtual tool revolutionizing patient consultations. Designed to leverage a patient's unique biometry, GreenMan offers a tangible visualization of post-surgery vision outcomes, empowering informed decision-making and improving satisfaction. Our experts discuss the clinical challenges that inspired this solution, detailing how they integrated GreenMan into their practice workflow. Learn how this advanced technology enhances patient education, streamlines lens selection, and delivers better visual outcomes. Want to see GreenMan in action? Click here to view the demo. Tune in to discover how GreenMan is setting a new standard in personalized eyecare.

In this episode, we explore GreenMan, an innovative virtual tool revolutionizing patient consultations. Designed to leverage a patient's unique biometry, GreenMan offers a tangible visualization of post-surgery vision outcomes, empowering informed decision-making and improving satisfaction. Our experts discuss the clinical challenges that inspired this solution, detailing how they integrated GreenMan into their practice workflow. Learn how this advanced technology enhances patient education, streamlines lens selection, and delivers better visual outcomes. Want to see GreenMan in action? Click here to view the demo. Tune in to discover how GreenMan is setting a new standard in personalized eyecare.

In this podcast, expert clinicians will discuss advances in biometry and IOL platforms.

This week we're joined by coach and mentor, Amy Snow. What is coaching? What is mentoring? What are the differences between the two? That's what we'll be discussing!Amy is a former Division I soccer player and lifelong participant in sports who loves what being an athlete has done for her in every aspect of her life. She graduated from Cornell University with a Bachelor's in Statistics and Biometry and a Master of Arts in Teaching (M.A.T.). She captained the varsity soccer squad her junior and senior years, was named Ivy League Rookie of the Year her freshman year and earned multiple All-Ivy honors and Athletic Academic All-American status during her tenure there. She was also inducted into the New York State Girls Soccer Hall of Fame in 2018.  And while she imagined the transition from sports would be hard, she didn't know how hard…until she got there. That is why she is also passionate about helping college and professional athletes manage their transitions from sports to their new careers. Helping them to create a game plan, challenging them to push themselves in new ways, and ultimately getting them to their goals faster than they could on their own is incredibly rewarding and energizing! 

Is there really a gold standard for biometry? In this episode of Peer2Peer: The Podcast, host Professor Gerd Auffarth leads a discussion on important biometry considerations with guest and internationally renowned expert, Dr. Nino Hirnschall. As we become more and more overwhelmed by new technologies, it can be difficult to decide which device(s) to use and more importantly, which one to trust.  Biometric measurements for IOL calculation have transformed from just basic parameters to more detailed measurements of the eye with more specific parameters. Are these new technologies fool proof? What kind of problems can still occur, even after using the newest, most advanced technology?  Listen in as Professor Auffarth and Dr. Hirnschall examine these questions and provide their tips and tricks of how to navigate through the various biometry options today.   The disclaimer for this episode is available in the show notes at rayner.com/peer2peer

For over 40 years, Dr. Ronnie Coffman has indefatigably empowered remarkable cadres of people in the pursuit of better lives for people in some of the world's most populous countries. He has dedicated himself to helping smallholder farmers with scarce resources whose lives are frequently bypassed by agricultural science and innovation. Dr. Coffman is the vice-chair of the Borlaug Global Rust Initiative, an international consortium of more than 1,000 scientists from hundreds of institutions working together to protect the world's wheat supplies. The global effort was launched in 2005 in partnership with CIMMYT, ICARDA, FAO and the late Norman E. Borlaug. He is currently principal investigator for a wide-range of international projects focused on food security and global development, including: Delivering Genetic Gain in Wheat and NextGen Cassava. In 2013, he won the inaugural World Agriculture Prize for his achievements guiding scientific and social change across continents and generations. In 2019 he was elected a fellow of the American Association for the Advancement of Science (AAAS) for his distinguished contributions to food security, including innovative research programs, support for women throughout science, and development of worldwide science communication programs. Dr. Coffman strongly supports gender initiatives that promote professional development for young women scientists. In 2011, he was honored with the Mentoring Award from the Women in Agronomy, Crops, Soil and Environmental Sciences. In 2013, when he won the inaugural World Agriculture Prize, he donated the $50K award to Advancing Women in Agriculture through Research and Education (AWARE), an initiative at Cornell whose members believe that empowering women as an underserved group holds the greatest potential to make significant impacts in agricultural development. He was also integral in establishing the West Africa Centre for Crop Improvement (WACCI) program in Ghana, a program that educates and trains the next generation of plant breeders for Africa, in Africa. WACCI celebrated its 13th anniversary in 2020. Previous positions include Associate Dean for Research (1993-2001); Director of the Cornell University Agricultural Experiment Station (1993-2001); Chair of the Department of Plant Breeding and Biometry (1987-1993); and Plant Breeder at the International Rice Research Institute (IRRI). Coffman's work has been important to the development of improved rice varieties grown on several million hectares throughout the world. He has collaborated extensively with institutions in the developing world and has served as a board member for several international institutes. Dr. Coffman grew up on a farm in Kentucky, and completed his undergraduate and master's degrees at the University of Kentucky. His Ph.D. is from Cornell, for which Norman E. Borlaug served on his thesis committee and oversaw his research, and with whom Coffman had a lifelong association.

Dr. Lori Provencher is joined by special guest host Dr. Ike Ahmed guest editor of the 2021 Ophthalmology Intraocular Lens Article Collection. Together they interview Dr. Jack Kane on his article, “Intraocular Lens Power Formulas, Biometry, and Intraoperative Aberrometry.” Intraocular Lens Power Formulas, Biometry, and Intraoperative Aberrometry. Kane, Jack X. et al. Ophthalmology, Volume 128, Issue 11, e94 - e114

In this Podcast, Ken Miller talks with Dr. Jack M Guralnik about outcome measures and the New Toolbox II resource from the Home Health Academy.  Dr. Jack Guralnik is currently Professor of Epidemiology and Public Health at the University of Maryland School of Medicine. He spent 25 years doing research at the National Institute on Aging and was Chief of the intramural Laboratory of Epidemiology, Demography and Biometry. He received his M.D. degree from Jefferson Medical College in Philadelphia and M.P.H. and Ph.D. degrees from the University of California, Berkeley. He is Board Certified in Public Health and General Preventive Medicine. Kenneth L Miller, PT, DPT is a board-certified geriatric clinical specialist, advanced credentialed exercise expert for aging adults and credentialed clinical instructor from APTA. He has over 26 years of clinical practice with the older adult population. Dr Miller is an assistant professor at the University of North Texas Health Science Center with dual appointments in the Department of Physical Therapy in the School of Health Professions and in the Department of Internal Medicine and Geriatrics in the Texas College of Osteopathic Medicine.    

Current senior Finbarr tells us about  campus life at Cornell before and during Covid. Listen to his Cornell experiences, highlights, and what's next when he graduates in May. We could not believe all the things he has done, but mostly we are stuck on the Sushirito truck. And did we mention he's our best friend's son?(Not affiliated with or sponsored by Cornell University)Instagram: https://www.instagram.com/cornellthanku/

In 2017, the 2nd Interventions in Aging Conference on "Understanding Mechanisms & Compressing Morbidity in Aging Humans" was held in Cancun, Mexico. The co-chairs of this conference, and speakers in this Aging (Aging-US) video, are Drs. Dame Linda Partridge DBE, FRS, FRSE, FMedSci, and Brian Kennedy Ph.D. Dr. Partridge is currently the Weldon Professor of Biometry in the Department of Genetics, Evolution and Environment at the University College London (UCL), Director of UCL's Institute of Healthy Ageing, and the Founding Director of the Max Planck Institute for the Biology of Ageing. Dr. Kennedy is a Distinguished Professor in the Department of Biochemistry and Physiology at the National University of Singapore (NUS)'s Yong Loo Lin School of Medicine. Dr. Kennedy is also Director of the National University Health System (NUHS) Centre for Healthy Ageing in Singapore, Professor at the Buck Institute for Research on Ageing, Adjunct Professor at the University of Southern California's Leonard Davis School of Gerontology, and Affiliate Faculty in Department of Biochemistry at the University of Washington. In this video, these two prominent researchers briefly discussed the state of aging research in 2017, and postulated what the future of aging interventions may look like. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.101221 DOI - https://doi.org/10.18632/aging.101221 Full Text - https://www.aging-us.com/article/101221/text#fulltext Correspondence to: Brian K. Kennedy email: bkennedy@buckinstitute.org and Linda Partridge email: partridge@age.mpg.de Keywords: healthspan, organismal aging, epigenetics, longevity, cellular mechanisms, metabolism, aging, conference About Aging (Aging-US) Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at http://www.Aging-US.com​​ or connect with us on: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/agingus​ LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Aging-US is published by Impact Journals, LLC please visit http://www.ImpactJournals.com​​ or connect with @ImpactJrnls Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

What's the cause of fetal growth restriction? How can you prevent it? In this episode of True Birth, we will talk about fetal growth restriction/FGR previously termed IUGR or Inner Uterine Growth Restriction.       What is FGR? [1:36] It is when the baby falls below the 10th percentile for weight. 10% of babies will be below the 10th percentile, by definition. Hence, 10% of babies will be classified as fetal growth restricted. It's important for you to know that because 10% of babies are not in a pathological situation. They're not in a bad situation. They're not in a situation where they're not growing.    [2:35] It's important to consider each woman and her partner uniquely in pregnancy.  A women that is  5'9 with women and a woman that is 5 feet tall will have different size expectations and patterns when it comes to pregnancy.    Possible reasons that the baby is small [4:17] The number one reason that a baby could be on the smaller side is that the mother is small and the father of the baby is maybe not the tallest guy. We use the term FGR/Fetal Growth Restriction when they're in utero, but once they're delivered, we call them SGA/Small for Gestational Age.    [5:06] When you find the baby's not growing well, this will generally be after 20 weeks Babies are generally the same size until 20 weeks.    [6:08] Another reason the baby is small is that it's supposed to be small and there's nothing wrong. The number two reason is placental perfusion. It has a problem with the baby getting enough blood flow and nutrients. It is just not getting enough of what it needs to grow well. And there are many reasons why the placenta won't function. So when you see a small baby, especially in the third trimester after 27 weeks, 30 weeks, start thinking, "Oh, how are her blood pressures? She's spilling protein. Is there something going on with this patient that's pointing me towards preeclampsia?"   [8:07] TORCH is an acronym that stands for toxoplasmosis, rubella cytomegalovirus, herpes simplex, and HIV. Cytomegalovirus is a virus that's very common in the population. Most people have been exposed to cytomegalovirus. T  Ultrasound tools [12:09] To understand Dopplers without getting into the physics of what the Doppler effect is, you can take your transducer, you could put it over the cord, and you can turn on the Doppler and you could see the blood flow through the cord.   [13:48] When you look at a Doppler, and you see the blood flowing the way it should, before the next heartbeat, you measure how fast it's going right before the next heartbeat.   [15:14] When you talk about fetal growth restriction, you can't just talk about the baby's size because there's only one piece of it. The other piece is what is the placenta telling you? What are the Dopplers telling you?    [15:34] Biometry is when you measure the femur and the abdomen and measure the head to get the size and weight of the baby and estimated fetal weight.    Guidelines about how to approach Fetal Growth Restriction [18:12] If you're below the third percentile, even if everything else is okay, that's the baby you got to deliver at 37 weeks. You can't just sit around and look at that baby for 37 weeks get the baby out. If your baby is above the third percentile and the Dopplers are elevated but not absent, get the baby up. And if there's no flow, the blood stops, that's even more concerning. If you see the reverse flow, you're dealing with a much more ominous situation and you don't want to go past 32 weeks. If you don't think the baby's doing well, you might have to come out even earlier.   Biophysical profile [22:09] One of the things that some patients might have to consider in other practices is that they would need to start having biophysical profiles done. A biophysical profile is when you're checking for a series of four different things and looking to ensure that the baby is reassuring overall. What is the baby's movement? What is fetal breathing, which is an exercise the baby does to inhale and exhale fluid? What is his tone? Is the baby flex or the floppy? Or if you feel the baby's not moving, these are things that you have to consider.   [23:51] One of the things you're looking for when talking about growth restriction is you want to see how the baby is handling the uterine environment? How's the baby doing on the inside? These tests will wish to you to identify a baby that's not doing well or not getting enough blood flow. You need to know if you can wait on it and let the baby stay inside, or is it time to get the baby out? Because then the baby will do better outside of the womb.    Recommendations [24:20] The recommendation is that if you recognize growth restriction, you should at least be monitoring weekly, that might be nonstress tests, or that might be a biophysical every week. And if you have a severe growth that restricts a baby under the third percentile or abnormal Dopplers or accident, then twice a week. If you have reversed outside flow, put those patients in the hospital because they need to be monitored around the clock and you got to pull the baby out before it's too late.     [29:08] The most reliable and consistent way to assess blood flow to the baby is the umbilical artery. Look at the ductus phimosis. When the umbilical cord hits the baby's belly button, a big part of the vein goes up into the heart carrying the birth at heart, and you can see if there's resistance, or even at the umbilical vein.   Here is the photo that we have permission to share.    Visit https://www.truebirthpodcast.com/ to listen more episodes! Maternal Resources Social Facebook: https://www.facebook.com/maternalresourceshackensack |nstagram: @maternalresources Subscribe to the podcast on Apple Podcasts, Spotify, Google Podcasts, & Stitcher and leave a review!          

Annemarie Koster is an Associate Professor at the Department of Social Medicine at Maastricht University. After receiving her PhD degree in 2005, she obtained an American fellowship at National Institutes of Health (NIH), National Institute on Aging (NIA) in Bethesda, MD, USA. Within the Laboratory of Epidemiology, Demography, and Biometry with Dr. Tamara B. Harris, she continued her research in the field of aging. From 2006 until 2011, Dr. Koster worked at NIA and her research focused on causes and consequences of obesity, changes in body composition, and physical (in)activity in old age. In 2011, she returned to Maastricht University and where she is currently an Associate Professor at the Department of Social Medicine. Additionally, she is a member of the Management Team of The Maastricht Study (http://www.demaastrichtstudie.nl/), the largest observational study worldwide on type 2 diabetes. Her current research focuses on objectively measured physical activity and is aimed at understanding the health consequences of physical inactivity and obesity. Moreover, Dr Koster and her group are particularly interested in the health effects of sedentary behaviour. --- This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research --- Collect, store and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://sens.fibion.com/ ---

Annemarie Koster is an Associate Professor at the Department of Social Medicine at Maastricht University. After receiving her PhD degree in 2005, she obtained an American fellowship at National Institutes of Health (NIH), National Institute on Aging (NIA) in Bethesda, MD, USA. Within the Laboratory of Epidemiology, Demography, and Biometry with Dr. Tamara B. Harris, she continued her research in the field of aging. From 2006 until 2011, Dr. Koster worked at NIA and her research focused on causes and consequences of obesity, changes in body composition, and physical (in)activity in old age. In 2011, she returned to Maastricht University and where she is currently an Associate Professor at the Department of Social Medicine. Additionally, she is a member of the Management Team of The Maastricht Study (http://www.demaastrichtstudie.nl/), the largest observational study worldwide on type 2 diabetes. Her current research focuses on objectively measured physical activity and is aimed at understanding the health consequences of physical inactivity and obesity. Moreover, Dr Koster and her group are particularly interested in the health effects of sedentary behaviour. --- This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research --- Collect, store and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://sens.fibion.com/ ---

Dolphins! Nepal! Florida! Well rounded and honest, Nilesh sits down with Carter about the research and experience Dr. Timilsina has encountered. Hailing all the way from Kathmandu, Nepal, Nilesh has experience managing projects related to ecosystem service assessment and optimization and carbon dynamics in forest ecosystems. He has done Spatial analysis and creating maps in GIS, Coordinating and conducting field data collection in Florida. Reach out for possible research opportunities in the coming future!

In this podcast episode, Karolinne Rocha, MD, PhD*, and Elizabeth Yeu, MD, discuss the field of ocular biometry, including useful IOL power calculation formulas, as well as considerations taken for post-LASIK eyes and patients with astigmatism. They also review how they utilize the TECNIS SymfonyTM Extended Range of Vision IOLs (Johnson & Johnson Vision) for their patients.  *Drs. Karolinne Rocha and Elizabeth Yeu are paid consultants of Johnson & Johnson Surgical Vision, Inc.

In this podcast episode, Karolinne Rocha, MD, PhD*, and Elizabeth Yeu, MD, discuss the field of ocular biometry, including useful IOL power calculation formulas, as well as considerations taken for post-LASIK eyes and patients with astigmatism. They also review how they utilize the TECNIS SymfonyTM Extended Range of Vision IOLs (Johnson & Johnson Vision) for their patients.*Drs. Karolinne Rocha and Elizabeth Yeu are paid consultants of Johnson & Johnson Surgical Vision, Inc.

Angle Kappa is one of those terms that gets thrown about at every ophthalmology meeting but does anyone really know what it means, what to do with that information or even what angle kappa really is? Your Ophthalmology Against The Rule hosts explain in simple language everything you want or need to know about angle kappa. They also discuss the real life practicalities of when and where this information is useful and why you may want to consider angle kappa when selecting an IOL for cataract surgery.

Your Ophthalmology Against The Rule hosts Dr Ben LaHood and Dr Nick Andrew discuss the latest evidence and their views on refining the outcome of second eye cataract surgery. Modern IOL calculation formulae are very good at predicting a refractive outcome but not yet perfect. Can we improve any further by considering how the first eye responded to surgery? This may seem like a simple question on the surface but there are other issues to consider such as biometry error and IOL manufacturing tolerances. This lively discussion is sure to make you think about how you tackle this scenario and may change your practice.

Oliver Findl talks to Nino Hirnschall about what young ophthalmologists need to know about ocular biometry.

Guests: Nick Mamalis, MD Professor University of Utah Department of Ophthalmology and Visual Sciences Salt Lake City, UT Michael Greenwood, MD  Clinical Instructor of Surgery University of North Dakota School of Medicine and Health Sciences Fargo, N.D.

Guests: George O. Waring IV, MD Assistant Professor of Ophthalmology Director of Refractive Surgery  Storm Eye Institute Medical University of South Carolina (MUSC) Charleston, South Carolina Claudia Perez-Straziota, MD Cleveland, OH

Passwords and pins are passé. A recent study shows that at least 770 million biometric authentication applications will be downloaded worldwide by 2019. The numbers are staggering, 65% of mobile transactions will be secured using biometrics by 2020 and 99% of smartphones will be biometrically enabled by 2021. In the Internet of Things (IoT), it is reported that more than 20 billion objects may end up connected. All of these devices will either need many more passwords — which will be impossible to remember and/or hard to protect — or unique biometric information to identify us. Biometry operates in three different modalities. They can be a human feature like your fingerprint, iris, or the shape of the veins on the back of your hands, facial recognition and many other physical features. They can be behavioral like the way we walk and run, or the way we hold our phones. Behavorials are based on the repetitive way we behave, and such data can be used to build motion repertoires, or a collection of habits, which define us. Or they can be physiological, which is the data that comes from the live function of our bodies. Examples of the latter would be voice recognition, heart rhythms, or brain activities. And in our case, the same technology can be used for strong encryption in addition to identification and authentication. Aerendir Mobile Inc.™ is the pioneer of a novel physiologic biometric authentication system called NeuroPrint™ (NP™). This novel identification and authentication biometric technology, which they refer to as the Touch Technology™ captures live signals from the individual’s unique brain cortex and motricity. The neuro-proprioceptive system sends unique NeuroPrint™ signals that can be sensed by existing hardware in smartphones and tablets without the need of any other internal or external device. This unique signals are nearly impossible to hack. Martin Zizi, MD-PhD, CEO of Aerendir joins me on my daily tech podcast. We discuss his invention of Neuro Print™, the cloudless physiological biometrics technology for authentication, identification, and encryption.

Guests: John D. Odette, MD Austin Eye Austin, TX Oliver Findl, MD Chair of the Department of Ophthalmology Hanusch Hospital Vienna , Austria

Guests: Edward J. Holland, M.D. Director, Cornea Services Professor of Ophthalmology University of Cincinnati Cincinnati, OH Kathryn Masselam Hatch, M.D. Director, Refractive Surgery Service Massachusetts Eye and Ear Infirmary Boston, MA

Christophe Remillet the CEO and Founder of OneVisage joins Future Tech Podcast to share his unique insight into OneVisage, a Swiss-based cybersecurity company that develops premium authentication and identification solutions. OneVisage is a leading biometry platform provider that helps financial services and Identity & Access Management (IAM) providers to reduce identity frauds and transaction cancellations. Their solutions are based on 3DAuth, the world's first 3D facial authentication technology that runs on consumer-grade mobile devices. Trusting in people, mobile devices, and 3D computer vision to build a safer, simpler and more cost effective digital world.

Guests: Ehud Assia, MD Professor of Ophthalmology Tel-Aviv University Medical School Tel-Aviv, Israel Jeffrey Whitman, MD   Dallas, TX

Guests: Oliver Findl, M.D. Chair of the Department of Ophthalmology Hanusch Hospital Vienna , Austria Cordelia Chan, M.D. Visiting Senior Consultant Singapore National Eye Centre Singapore

Hosts: Dickson Despommier and Vincent Racaniello Guest: Gene Giacomelli Dickson and Vincent speak with Professor Gene Giacomelli about his work on controlled environment plant production systems research, design, development and applications.   Links for this episode Controlled environment agriculture Biometry and biosystems informatics Food, bioproducts, and renewable energy Image credit This episode is sponsored by CuriosityStream, a subscription streaming service that offers over 1,400 documentaries and non­fiction series from the world’s best filmmakers. Get unlimited access starting at just $2.99 a month, and for our audience, the first two months are completely free if you sign up at curiositystream.com/microbe and use the promo code MICROBE. Send your questions and comments to urbanag@microbe.tv

Ryan Hernandez is an assistant professor at UC San Francisco in the department of Bioengineering and Therapeutic Sciences. Playing sports was his top priority in high school, but encouragement from one of his teachers led him pursue a major in mathematics in college. As an undergraduate, Hernandez's interest in population genetics sprung from his curiosity about how and why his grandmother developed diabetes. He wanted to try to design a model to show the interaction between blood glucose, insulin and insulin receptors that leads to the onset of diabetes. Hernandez went on to earn his PhD in Biometry from Cornell University. The Hernandez lab at UCSF uses data from human genomes to study patterns of genetic variation between populations. This video is one of three in the Career Spotlight: Biotechnology series.

Melvyn Bragg and guests discuss mutation in genetics and evolution. When lying mortally ill with cancer, the British geneticist J.B.S. Haldane penned the following lines: Cancer's a Funny Thing:I wish I had the voice of HomerTo sing of rectal carcinoma,Which kills a lot more chaps, in fact,Than were bumped off when Troy was sacked...Haldane knew better than most that many cancers, and many other diseases, are caused by genetic mutation. A mutation is an error in reproduction between one generation and the next as the copying mechanism that allows you to inherit your parent's genes goes awry. Mutations are almost always bad news for the organism that suffers them and yet mutation is also a giver of life. Without it there would be no natural selection, no evolution and, arguably, no life on this planet. It's not unreasonable to see life itself as a mutation and to understand this may also hold the key to aging and disease. It is, in the Darwinian view of life, the raw material of evolution.With Steve Jones, Professor of Genetics in the Galton Laboratory, University College London; Adrian Woolfson, lectures in Medicine at Cambridge University; Linda Partridge, Weldon Professor of Biometry at University College LondonTags

Melvyn Bragg and guests discuss mutation in genetics and evolution. When lying mortally ill with cancer, the British geneticist J.B.S. Haldane penned the following lines: Cancer's a Funny Thing:I wish I had the voice of HomerTo sing of rectal carcinoma,Which kills a lot more chaps, in fact,Than were bumped off when Troy was sacked...Haldane knew better than most that many cancers, and many other diseases, are caused by genetic mutation. A mutation is an error in reproduction between one generation and the next as the copying mechanism that allows you to inherit your parent’s genes goes awry. Mutations are almost always bad news for the organism that suffers them and yet mutation is also a giver of life. Without it there would be no natural selection, no evolution and, arguably, no life on this planet. It’s not unreasonable to see life itself as a mutation and to understand this may also hold the key to aging and disease. It is, in the Darwinian view of life, the raw material of evolution.With Steve Jones, Professor of Genetics in the Galton Laboratory, University College London; Adrian Woolfson, lectures in Medicine at Cambridge University; Linda Partridge, Weldon Professor of Biometry at University College LondonTags